Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in HFpEF (VITALITY-HFpEF)
NCT03547583Phase 2Completed
- Sponsor
- Bayer
- Start
- Jun 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial of Vericiguat oral suspension (Formulation 4) in heart failure with preserved ejection fraction (HFpEF) (3 arms), sponsored by Bayer. Primary endpoint: Change in Kansas City Cardiomyopathy Questionnaire Physical Limitation Score at 24 weeks. Started Jun 2018; status: completed.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03547583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03547583.